KINEVANT

Kinevant Sciences (kine-a-vant) is a clinical-stage biopharmaceutical company dedicated to treating rare inflammatory and autoimmune diseases with significant unmet need. Our lead candidate namilumab targets GM-CSF, a key pro-inflammatory cytokine involved in the pathogenesis of inflammatory disorders... Diseases shouldn't define us. We are dedicated to improving patients' quality of life, so they spend less time on the sidelines and more time on the move.

Also known as: Kinevant Sciences, Kinevant Sciences, Inc.

Primary location: New York United States